Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01772147 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 608
- Enrollment target
NCT01772147 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 608 participants.
The verdict
NCT01772147, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 608 participants
- Enrollment target
Study Summary
The purpose of this 12 week study is to evaluate the effects of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticasone propionate (250/50mcg) twice-daily and umeclidinium bromide (125mcg) once-daily to fluticasone propionate (250/50mcg) twice-daily with placebo when added to fluticasone propionate (250/50mcg) twice-daily on lung function, COPD-related health status assessments and safety in COPD subjects.
Interventions
- DRUG Umeclidinium bromide 62.5mcg
- DRUG Umeclidinium bromide 125mcg
- DRUG Fluticasone propionate 250mcg/Salmeterol 50mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 608 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01772147
The ClinicalTrials.gov registry entry for NCT01772147 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 608 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Umeclidinium bromide 62.5mcg is the first listed.
NCT01772147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01772147 about?
NCT01772147 is a clinical study titled "Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.". The purpose of this 12 week study is to evaluate the effects of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticasone propionate (250/50mcg) twice-daily and umeclidinium bromide (125mcg) once-daily to fluticasone propionate (250/50mcg) twice-daily with placebo when added to flutic...
What is the current status of trial NCT01772147?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 608 participants. The study started on 2013-01. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01772147?
The interventions under investigation include: Umeclidinium bromide 62.5mcg (DRUG), Umeclidinium bromide 125mcg (DRUG), Fluticasone propionate 250mcg/Salmeterol 50mcg (DRUG).
Who is sponsoring clinical trial NCT01772147?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.